Bausch & Lomb Corp
Company Profile
Business description
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Contact
520 Applewood Crescent
VaughanONL4K 4B4
CANT: +1 905 695-7700
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2025
Employees
13,300
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,543.70 | 34.10 | -0.40% |
CAC 40 | 7,431.04 | 59.24 | -0.79% |
DAX 40 | 20,214.79 | 102.31 | -0.50% |
Dow JONES (US) | 41,938.45 | 696.75 | -1.63% |
FTSE 100 | 8,248.49 | 71.20 | -0.86% |
HKSE | 19,064.29 | 176.60 | -0.92% |
NASDAQ | 19,161.63 | 317.25 | -1.63% |
Nikkei 225 | 39,190.40 | 414.69 | -1.05% |
NZX 50 Index | 12,895.98 | 47.76 | -0.37% |
S&P 500 | 5,827.04 | 91.21 | -1.54% |
S&P/ASX 200 | 8,294.10 | 35.10 | -0.42% |
SSE Composite Index | 3,168.52 | 42.87 | -1.33% |